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ABSTRACT 
INTRODUCTION: Estrogen receptor beta (ERβ) over-expression by malignant 
pleural mesothelioma (MPM) tumor cells correlates with enhanced patient survival. 
ER-regulated transcription is mediated by the p160 family of steroid receptor 
coactivators (SRCs) and SRC isoform over-expression is associated with worse 
prognosis in many steroid-related malignancies. The aim of this study was to 
establish whether SRC isoform expression varied between individual MPM tumors 
with positive or negative prognostic significance. 
METHODS: Immunohistochemical analysis of tumor biopsies from 89 subjects with 
confirmed histological diagnosis of MPM and biopsies from 3 normal control subjects 
was performed to detect the expression of SRC-1, SRC-2 (TIF-2), SRC-3 (AIB-1) and 
ERβ. Allred scores for expression of ERβ and each of the SRCs were determined, 
and Kaplan-Meier survival curves calculated to correlate biomarker expression, 
gender and histology-type with post-diagnosis survival. 
 RESULTS: ERβ and all of the SRCs was expressed at high levels in normal pleural 
mesothelium and expression of each biomarkers was reduced or lost in a subset of 
the MPM subjects; however, post diagnosis survival only significantly correlated with 
TIF-2 expression. Low or intermediate expression of TIF-2 correlated with reduced 
median post diagnosis survival (9 months) compared to those subjects whose tumors 
highly expressed TIF-2 (20 months) (P = 0.036, log-rank test).   
CONCLUSIONS: Maintained high expression of TIF-2 in tumor cells is a positive 
prognostic indicator for post-diagnosis survival in patients with confirmed MPM. This 
is the first clinical study to correlate high TIF-2 expression with improved patient 
prognosis in any malignancy. 
 
Key Words 
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INTRODUCTION 
Malignant pleural mesothelioma (MPM) is a rare but highly aggressive tumor that 
arises from the mesothelial surfaces of the pleura1. A causative link has been 
established between exposure to asbestos fibres and the subsequent development 
of MPM in 85% of subjects, while simultaneous infection with SV40 virus is also 
believed to contribute to MPM etiology2. MPM is often detected decades after initial 
exposure to the carcinogen; however, there is also a genetic contribution that 
predisposes individuals to developing this malignancy3. MPM is invariably terminal 
and histological sub-typing is currently the most important prognostic indicator of post 
diagnosis survival time4. Patients diagnosed with epithelioid MPM have a mean post 
diagnosis survival period of 16.3 months, while patients with sarcomatoid or biphasic 
MPM have a poorer prognosis with mean post diagnosis survival times of 6.1 months 
and 9.5 months respectively5. The estimation of prognosis based solely on 
histological typing is imprecise since up to 70% of all MPM cases are of epithelioid-
type and considerable variation occurs in the actual survival times for patients within 
this subgroup. Additional prognostic markers are required in order to further sub-type 
MPM cases and so more effectively refine patient treatment regimes.    
 
Female gender is a positive prognostic factor in MPM survival5-7, and this protection 
is at least partially mediated through the action of estrogen receptor beta (ERβ)8. ER-
mediated transcription initiation occurs when ligand-bound ER interacts with gene 
promoter sequences and recruits steroid receptor coactivators (SRCs) to promote the 
formation of the transcription pre-initiation complex9. The p160 family of coactivator 
proteins make a rate-limiting contribution to the formation of this complex and so 
rigidly control transcriptional responses stimulated by all steroid hormones. The p160 
family is comprised of steroid receptor coactivator-1 (SRC-1/NCoA-1)10, 
transcriptional intermediary factor 2 (TIF-2/SRC-2/GRIP-1/NCoA-2)11 and amplified in 
breast cancer-1 (AIB-1/SRC-3/NCoA-3)12. Dysregulation of p160 SRC expression 
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affects tumour cell proliferation and invasive capacity; this occurs in all steroid-
sensitive malignancies including prostate carcinoma13 and endometrial carcinoma12. 
The contribution of SRCs to tumorigenesis is best characterized in the context of 
breast carcinoma where AIB-1 is defined by its up-regulation in the most aggressive 
tumors12 and confirmed by the observation that AIB-1 over-expression in a mouse 
model resulted in the spontaneous generation of mammary tumors14.  
 
The overall effect of estrogen action on tumor cell biology is complex, particularly in 
tissues that express both ERα and ERβ15. There is growing evidence of a protective 
role for ERβ expression and activation in some malignancies, including colorectal 
carcinoma16 and MPM8. In the context of colorectal carcinoma, ERβ is highly 
expressed by differentiated cells of the colonic epithelium and its expression is lost in 
the most aggressive of tumors and correlates with poor prognosis16. The dependency 
of this ERβ tumor-suppressor effect on differential SRC expression has not been 
investigated and raises the possibility that in specific, ERβ-attenuated malignancies, 
SRCs may also have a tumor-suppressive role. Indeed in colon carcinoma the 
elevated expression of AIB-1 correlates with improved patient survival17. Thus, in 
contrast with estrogen-stimulated malignancies such as breast carcinoma or 
endometrial carcinoma, the loss of specific SRC expression could diminish the 
protective effects exerted by ERβ and so be a negative prognostic indicator. The 
aims of this study were to evaluate expression of SRC-1, TIF-2 and AIB-1 in tumors 
from a cohort of patients with confirmed MPM diagnosis using immuno-
histochemistry (IHC), to relate SRC expression in tumor cells to patient survival and 
to compare the prognostic efficacy of SRC isoform expression with other indicative 
parameters of post diagnosis survival.   
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MATERIALS and METHODS 
Patients and Tissue Samples 
Eighty-nine confirmed cases of MPM and three control subjects were identified from 
the archival pathology files of the Pathology Unit of the Regional Hospital of Mestre-
Venice, Italy. All diagnoses of MPM were based on World Health Organization 
criteria, and confirmed in all instances by clinical, morphological and IHC data. The 
tissue samples were taken following videothoracoscopy biopsy or from resected 
surgical specimens. The tissue samples were fixed in neutral formalin and embedded 
in paraffin. Permission for tissue to be used for research purposes was obtained 
according to local ethical procedures and following informed patient consent. Clinical 
data relating to each of the subjects was obtained with consent from primary patient 
records and coded before analysis by researchers. 
 
Immuno-histochemistry 
IHC parameters for the ERβ and p160 SRC family specific-antibodies were initially 
optimized using a breast carcinoma tissue micro-array. IHC analysis for each antigen 
was performed using a Bond III Automated IHC Stainer (Leica Microsystems, 
Wetzlar, Germany) on serial 4 μm depth tissue sections from each of the embedded 
specimens. Slides were treated for 20 min with Leica BondMax Epitope Retrieval 
Solution 1 (ER1) for detection of TIF-2 and Leica BondMax Epitope Retrieval 
Solution 2 (ER2) for detection of SRC-1, AIB-1 and ERβ to achieve post-sectioning 
antigen retrieval. Specific primary antibodies were applied as indicated: SRC-1 
(Clone 128E7, rabbit monoclonal antibody, 1:200; Cell Signalling Technology, 
Danvers, MA), TIF-2 (Clone 29, mouse monoclonal antibody, 1:100; BD Transduction 
Laboratories, San Jose, CA) and AIB-1 (Clone 34, mouse monoclonal antibody, 
1:200; BD Transduction Laboratories, San Jose, CA), ERβ (NCL-ERβ, mouse 
monoclonal antibody, 1.100; Novocastra, Leica Microsystems, Ashbourne, Ireland). 
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Primary antibodies were revealed using the Leica Bond Polymer Refine detection kit 
and the signal was enhanced using the Leica BondMax DAB enhancer kit. Slides 
were counterstained with haematoxylin before mounting and microscopic 
visualization. 
 
Scoring System 
Semi-quantitative determination of SRC-1, TIF-2, AIB-1 and ERβ was performed 
according to the criteria described by Allred et al.18. The proportion of positive stained 
cells was rated as 0 = no cells stained positive, 1 = between 0% and 1% positive, 2 =
between 1% and 10%, 3 = between 10% and 33%, 4 = between 33% and 66%, and 
5 = between 66% and 100%. In addition to the proportion score, an intensity score 
was made on the basis of the average intensity of staining: 0 = negative, 1 = weak, 2
= intermediate and 3 = strong. The proportion score and the intensity score were 
added to obtain the total score, and is either 0 or between 2 and 8. Allred scores of 6 
or greater were interpreted as strong staining. Slides were independently evaluated 
and scored in a blind fashion by two independent observers. Any discrepancies in 
scoring between the observers were resolved by review of the slides under a double-
headed microscope and a consensus score was allocated. 
 
Statistical Analysis 
Differences in post diagnosis survival were calculated using Kaplan-Meier analysis 
and survival curves were generated using the TMA Foresight package (TMA 
Foresight 3.01, Premier Biosoft International, Palo Alto, CA). P-values were 
calculated using a log-rank test 19 and a P-value <0.05 was taken to be indicative of 
statistical significance between populations. The multivariate Cox proportional hazard 
regression model was then used to calculate hazard ratios and to stratify the 
variables for known clinical parameters20. This ensures that the prognostic markers 
are independent of known clinical parameters (gender, tumor histological-type, age at 
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diagnosis and chemotherapeutic intervention). All calculations were performed using 
the survival library of the open source R package (http://cran.r-project.org/) and the 
two-tailed Wald test was applied.  
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RESULTS 
Patient Cohort Characteristics 
SRC isoform and ERβ expression was determined using IHC in tumor biopsy 
specimens for a well-defined cohort of MPM subjects with >5 years post diagnosis 
follow-up. Paraffin embedded tumor tissue samples from 89 patients with age range 
44 to 82 years (clinicopathological characteristics shown in Table 1) and 3 normal 
control subjects were analysed. The gender distribution of the MPM cohort was 73 
male and 16 female subjects; the median age at diagnosis was 64 years for male 
and 65 years for female subjects. Histological types were determined to be 71 (79.8 
%) epithelioid, 10 (11.2 %) biphasic and 8 (9.0 %) sarcomatoid. The majority of the 
subjects (n=64) had received cisplatin-based chemotherapy post diagnosis. Overall 
post-diagnosis Kaplan-Meier survival curves for histological-type and gender are 
shown (Fig 1). The median post-diagnosis survival time was 15 months for patients 
with epithelioid MPM, 10 months for subjects with biphasic mesothelioma and 6 
months for subjects with sarcomatoid mesothelioma (Fig 1.A). The median survival 
time for male subjects was 10 months and 18 months for female subjects (Fig 1.B). 
These survival data show that the MPM subjects in this present study have 
equivalent distribution and outcomes when compared with MPM subject cohorts from 
other studies in which patients with the epithelioid-type mesothelioma have better 
prognosis, followed by patients with biphasic mesothelioma, while patients with 
sarcomatoid mesothelioma have the worst prognosis5, 7. Previous studies have also 
found a gender dichotomy in patient outcome, with improved survival for female MPM 
patients5, 7, 8. Although not statistically significant for this cohort (P=0.101, log-rank 
test), these results in common with other published studies also indicate that female 
MPM subjects have a better prognosis than their male counterparts.  
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Normal pleura and malignant pleural mesothelioma tissue tumour samples 
express SRC-1, TIF-2 and AIB-1 
The p160 SRCs are required by all steroid nuclear receptors including the estrogen 
receptors to initiate ligand-dependent transcription9. The up-regulation of SRCs 
particularly AIB-1 in the context of breast carcinoma correlates with a more 
aggressive tumor phenotype in both estrogen-dependent and estrogen-independent 
tumors14. ERβ has been proposed as a tumor suppressor in colorectal carcinoma21, 
and its over-expression in MPM correlates with enhanced patient survival8. 
Comparative SRC expression in a MPM patient cohort has not previously been 
investigated. Here we found predominantly nuclear staining for each of the p160 
SRCs: SRC-1 and AIB-1 (Supplemental Figure 1), TIF-2 and also ERβ (Fig. 2) in all 
three normal pleural mesothelium tissue samples. All cells making up the normal 
mesothelial monolayer stained with high intensity for ERβ and each of the SRCs. For 
the 89 MPM subjects, there was marked variation in IHC staining intensity and the 
proportion of positively stained cells between the tumor specimens from the different 
subjects (Fig. 2). The Allred scoring system was applied to quantify staining in each 
of the tumor samples for the three p160 SRCs and ERβ (Table 2). A predominantly 
nuclear staining with Allred score ≥6 was observed in 39 (43.8 %) MPM subjects for 
SRC-1, 38 (42.7 %) subjects for TIF-2 and 52 (58.4 %) subjects for AIB-1. Low or 
intermediate staining (Allred score ≤5) was observed in 50 cases for SRC-1 (56.2 %), 
51 cases for TIF-2 (57.3 %) and 37 cases for AIB-1 (41.6 %). ERβ was also localized 
to the nuclei of stained cells negative staining (Allred score ≤3) was observed in 23 
cases (25.8%). 
 
Kaplan-Meier survival curves were calculated for subjects with high versus 
intermediate/ low Allred expression scores of SRC-1 (supplementary data), TIF-2 
(Fig 3A), AIB-1 (supplementary data) and positive versus negative ERβ expression 
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(Fig 4) in the individual tumor samples. Median post-diagnosis survival for subjects 
with high expression of SRC-1 was 14 months, while the median survival for subjects 
with intermediate/low expression was only slightly lower at 10 months. However, 
median survival for patients with high expression of TIF-2 was 20 months, while the 
median survival for patients with intermediate/ low expression was significantly lower 
at 9 months, thus patients with intermediate/low expression of TIF-2 showed a 
statistically worse outcome compared to patients with high levels of TIF-2 expression 
(P = 0.036, log-rank test). Median survival for patients with high or intermediate/low 
expression of AIB-1 was 12 months. Median survival of patients with high ERβ was 
15 months and for those with low ERβ was 8 months but was not statistically 
significant in this cohort (P = 0.254, log-rank test). 
 
TIF-2 Expression and Prognosis in Epithelioid and Male Only Subgroups  
Histological type and gender influence post diagnosis survival in MPM. Epithelioid 
histological type is a positive prognostic factor in MPM, while male gender is a 
negative prognostic factor. To determine if TIF-2 expression was of prognostic value 
when the outcome for epithelioid histology-type or for male subjects were analysed 
separately, Kaplan-Meier survival curves were calculated for high versus 
intermediate/ low TIF-2 expression in the tumors of subjects within these two 
subgroups. Median survival for subjects with epithelioid tumors (n = 71) that 
expressed high levels of TIF-2 was 23 months, while for those subjects with low or 
intermediate levels of TIF-2 expression had a median survival time of 9 months (P = 
0.031, log-rank test) (Fig 3B). Median survival of male patients (n = 73) with high TIF-
2 expression levels was 20 months compared to 8 months for male patients with low 
or intermediate levels of TIF-2 expression (P = 0.003, log-rank test) (Fig 3C).  
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Hazard Ratio  
Multivariate Cox proportional hazard regression analysis was performed correcting 
for gender (male, female); age at diagnosis (<60, 60-69, ≥70 years); histological type 
(epithelioid, biphasic sarcomatoid) and chemotherapeutic intervention (therapy, no 
therapy) (Table 3). The adjusted hazard ratio for high versus low/ intermediate TIF-2 
expression was 0.526 (0.301-0.918) (P = 0.0239, two-sided Wald test).  
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DISCUSSION 
MPM is a slow-developing malignancy with extremely poor patient outcome and 
limited availability of molecular markers to predict survival or therapeutic efficacy. In 
steroid-dependent malignancies of the reproductive tissues, over-expression of p160 
SRC family proteins correlates with a more aggressive tumor phenotype and worse 
prognosis14. The p160 SRCs form the scaffold for the assembly of the transcription 
pre-initiation complex and as such are key components in the induction of estrogen-
responsive genes. Dysregulation of p160 SRC action in breast carcinoma through 
over-expression and hyper-phosphorylation of the co-activators results initially in 
amplification of estrogen responses in tumor cells, and subsequently to uncoupling of 
cell growth from circulatory estrogen availability; so contributing to the switch from 
endocrine-dependent to growth factor-dependent tumor cell proliferation22. Recent 
data suggest that unusually, MPM cell proliferation may be slowed by circulating 
estrogens rather than accelerated8, and consequently the molecular machinery of 
ER-regulated transcription is recruited to tumor suppression rather than promotion. 
The anti-tumor action of estrogens is transduced through ERβ which regulates the 
expression of cell cycle regulators such as cyclin D1 8, 23. 
 
The strong dependency of ER transcriptional activity on SRC abundance led to our 
investigation of p160 SRC isoform expression in MPM tumors. Our study found that 
each of the p160 SRCs investigated: SRC1; TIF-2 and AIB-1 were highly expressed 
in normal pleural mesothelium from malignancy-free subjects, this novel observation 
suggested a role for these co-factors in the normal physiological processes of the 
pleural mesothelium. Each of the SRCs were also expressed in the majority of the 
MPM tumor specimens analysed; however, Allred immuno-histochemical scoring of 
SRC expression revealed that there was a declining trend in the expression of all 
three SRCs in tumors from MPM subjects with the shortest post-diagnosis survival 
time. The decline in TIF-2 expression correlated most strongly with reduced post-
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diagnosis survival, and TIF-2 expression was a more accurate predictor of outcome 
than previously identified indicators of survival (histological type and gender) in this 
cohort of MPM subjects. Further more, TIF-2 was a better predictor of post-diagnosis 
survival within the epithelioid tumor subjects than in the cohort as a whole, which 
included the biphasic and sarcomatoid tumor subjects. The loss of TIF-2 expression 
thus identified a subgroup of epithelioid tumors which were most likely to have 
reduced post-diagnosis survival. Whether this discriminates those subjects whose 
malignancy is most likely to progress and develop a sarcomatoid tumor phenotype 
remains to be established. 
 
ERβ is implicated as a tumor suppressor not only in MPM but also in breast24, 
25 prostate26 and in colon carcinoma; however, TIF-2 expression correlates 
with worse prognosis in colorectal carcinoma because colonic epithelium also 
expresses ERα that requires the SRCs for its transcriptional activity17. In 
general ERα transduces the proliferative action of estrogen, particularly in 
reproductive tissues. Since the normal pleural mesothelium expresses only 
ERβ8, it may be anticipated that the SRCs participate exclusively in the anti-
tumor actions of ERβ promoted by circulatory estrogens. The benefits of ERβ 
expression as manifest through slowed tumor cell growth may subside with 
the decline in TIF-2 expression that was observed in MPM subjects with the 
poorest post diagnosis survival times. In this cohort of patients ERβ 
expression was a weaker predictor of survival than TIF-2 expression  This 
study is the first clinical report of the transcription factor TIF-2 acting in the 
role of a tumor suppressor and as a potential signalling intermediate 
underpinning the positive prognostic effects of ERβ expression in MPM. 
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 Figure Legends 
Figure 1 
Kaplan-Meier survival curves for malignant pleural mesothelioma subject survival 
discriminated by histological type (A) and gender (B). 
 
Figure 2 
Representative immuno-histochemical staining (x200 magnification) TIF-2 (A-E) and 
ERβ (F-J) in normal pleural mesothelium (NM) and malignant pleural mesothelioma 
tumor tissue with Allred score (AS) values of 2, 4, 6 and 8. 
 
Figure 3 
Kaplan-Meier survival curves for malignant pleural mesothelioma subject survival 
discriminated by high versus low/ intermediate TIF-2 expression for the whole subject 
cohort (A); epithelioid cases only (B) and male subjects only (C). 
 
Figure 4 
Kaplan-Meier survival curve for malignant pleural mesothelioma subject survival 
discriminated by high versus low/ intermediate ERβ expression for the whole subject 
cohort. 
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Supplemental Figures 
Supplemental Figure 1 
Representative immuno-histochemical staining (x200 magnification) for SRC-1 (A-E), 
and AIB-1 (F-J) in normal pleural mesothelium (NM) and malignant pleural 
mesothelioma tumor tissue with Allred score (AS) values of 2, 4, 6 and 8. 
 
Supplemental Figure 2 
Kaplan-Meier survival curves for malignant pleural mesothelioma subject survival 
discriminated by high versus low SRC-1 expression (A) and high versus low AIB-1 
expression (B). 
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TABLE 1: Summary of subject characteristics at diagnosis and p160 SRC immuno-
histochemistry data (n=89). 
 
  Male  
(n = 73) 
Female  
(n = 16) 
All  
( n = 89) 
Age at diagnosis,  
median (range) 
64 (44-82) 65 (55-79) 64 (44-82) 
Histology Type, n (%) 
  Epitheloid 
  Biphasic 
  Sarcomatoid 
 
56  (76.7%) 
 9   (12.3%) 
 8   (11.0%) 
 
15   (93.7%) 
 1    (6.3%) 
 0    (0%) 
 
71   (79.8%) 
10   (11.2%) 
 8    (9.0%) 
Stage 
  T2 
  T3 
  T4 
  N0 
  N1 
  N2 
 
22  (30.1%) 
40  (54.8%) 
11  (15.1%) 
45  (61.6%) 
16  (21.9%) 
12  (16.4%) 
 
 5    (31.2%) 
 5    (31.2%) 
 6    (37.5%) 
14   (87.5%) 
  0   (0%) 
  2   (12.5%) 
 
27   (30.3%) 
45   (50.6%) 
17   (19.1%) 
59   (66.3%) 
16   (20%) 
14   (15.7%) 
  M0 
  M1 
73  (100%) 
  0  (0%) 
16   (100%) 
  0   (0%) 
89   (100%) 
  0   (0%) 
Surgery 
Yes 
No 
 
48   (65.75%) 
25   (34.25%) 
 
11   (68.75%) 
  5   (31.25%) 
 
59    (66.3%) 
30    (33.7%) 
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TABLE 2: Summary of subject p160 SRC, and ERβ immuno-histochemistry data 
(n=89). 
 
  Male  
(n = 73) 
Female  
(n = 16) 
All  
( n = 89) 
SRC-1 Expression 
  Low/Intermediate 
  High 
 
42   (57.5%) 
31   (42.5%)  
 
8     (50%) 
8     (50%) 
 
50    (56.2%) 
39    (43.8%) 
TIF-2 Expression 
  Low/Intermediate 
  High 
 
44    (60.3%) 
29    (39.7%) 
 
7     (43.8%) 
9     (56.2%) 
 
51    (57.3%) 
38    (42.7%) 
AIB-1 Expression 
  Low/Intermediate 
  High 
 
31    (42.5%) 
42    (57.5%) 
 
6     (37.5%) 
10   (62.5%) 
 
37    (41.6%) 
52    (58.4%) 
ERβ Expression 
  Negative 
  Positive 
 
19     (26%) 
54     (74%) 
 
4       (25%) 
12     (75%) 
 
23     (25.8%) 
66     (74.2%) 
 
 20
 
 
Table 3: Cox proportional hazards model of overall survival (n=89). 
 
TIF-2 Expression N HR (95% CI P* 
 
Low/Intermediate 
 
51 
 
1.00 
 
High Expression     38 0.526  
(0.301-0.918) 
0.0239 
 
*Two-sided Wald Test 
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